Order Article Reprints

Chen WH, Woolston J, Grant-Beurmann S, Robinson CK, Bansal G, Nkeze J, Permala-Booth J, Fraser CM, Tennant SM, Shriver MC, et al. Safety and Tolerability of ShigActive™, a Shigella spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial. Antibiotics. 2024; 13(9):858. https://doi.org/10.3390/antibiotics13090858

Chen, Wilbur H., Joelle Woolston, Silvia Grant-Beurmann, Courtney K. Robinson, Garima Bansal, Joseph Nkeze, Jasnehta Permala-Booth, Claire M. Fraser, Sharon M. Tennant, Mallory C. Shriver, and et al. 2024. "Safety and Tolerability of ShigActive™, a Shigella spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial" Antibiotics 13, no. 9: 858. https://doi.org/10.3390/antibiotics13090858

Chen, W. H., Woolston, J., Grant-Beurmann, S., Robinson, C. K., Bansal, G., Nkeze, J., Permala-Booth, J., Fraser, C. M., Tennant, S. M., Shriver, M. C., Pasetti, M. F., Liang, Y., Kotloff, K. L., Sulakvelidze, A., & Schwartz, J. A. (2024). Safety and Tolerability of ShigActive™, a Shigella spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial. Antibiotics, 13(9), 858. https://doi.org/10.3390/antibiotics13090858